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ABSTRACT 
 
Experimental models that faithfully mimic the developmental pathology of sporadic Alzheimer’s 
disease (sAD) in humans are important for testing the novel therapeutic approaches in sAD treatment. 
Widely used transgenic mice AD models have provided valuable insights into the molecular 
mechanisms underlying the memory decline but, due to the particular β-amyloid-related gene 
manipulation, they resemble the familial but not the sporadic AD form, and are, therefore, 
inappropriate for this purpose. In line with the recent findings of sAD being recognised as an insulin 
resistant brains state (IRBS), a new, non-transgenic, animal model has been proposed as a 
representative model of sAD, developed by intracerebroventricular application of the betacytotoxic 
drug streptozotocin (STZ-icv). The STZ-icv treated animals (mostly rats and mice) develop IRBS 
associated with memory impairment and progressive cholinergic deficits, glucose hypometabolism, 
oxidative stress and neurodegeneration that share many features in common with sAD in humans. 
The therapeutic strategies (acetylcholinesterase inhibitors, antioxidants and many other drugs) that 
have been tested until now on the STZ-icv animal model have been reviewed and the comparability of 
the drugs’ efficacy in this non-transgenic sAD model and the results from clinical trials on sAD 
patients, evaluated. 
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INTRODUCTION  
 
Alzheimer’s disease (AD) is a common neurodegenerative disorder clinically characterized by a 
progressive memory decline which becomes manifested after a long pre-symptomatic phase. In 
contrast to the rare, early-onset, familial form of AD caused by missens mutations of genes related to 
the β-amyloid (Aβ) pathological hyperproduction, the prevailing sporadic form of AD (sAD) with 
plaques and neurofibrillary tangles is not caused by such gene mutations. However, the exact cause 
of sAD is still unknown. Due to a specific nature of AD, the exploration of onset and progression of the 
biochemical changes in the brain is difficult, almost impossible to be performed during a life-time. 
Therefore, one has to rely on in vivo experimental models. Carrying the mutated Aβ-overproduction-
related gene as an inevitable starting point from the very beginning makes the widely exploited 
transgenic mice inappropriate models for exploring the cause, onset and development of the 
pathological Aβ deposition in the brain in conditions which are not associated with mutations of the 
APP gene. Despite of that, the therapeutic potential of various drug and non-drug anti-sAD strategies 
has been widely tested in the transgenic mice AD models (Zahs and Ashe 2010). 
 
In line with the hypothesis of sAD being the brain type of non-insulin dependent diabetes mellitus (DM) 
(Hoyer,1998), and studies which afterwards indicated the presence of insulin resistant brains state in 
AD patients post-mortem (Frölich et al. 1999; de la Monte et al. 2005; Steen et al. 2005; Hoyer 2004) 
and its progression with severity of dementia (as reviewed by Correia et al. 2011), a new, non-
transgenic rat model has been proposed as a representative model of sAD (Lannert and Hoyer 1998; 
Salkovic-Petrisic and Hoyer 2007). The model has been developed by intracerebroventricular (icv) 
application of the drug streptozotocin (STZ) (Mayer et al. 1991). Following the parenteral 
administration of high doses, STZ selectively destroys insulin producing/secreting β cells in the 
pancreas, causing DM type I in adult animals (Szkudelski 2001), while multiple parenteral treatment 
with low to moderate STZ doses causes insulin resistance by damaging insulin receptor (IR) signalling 
(Blondel and Portha 1989; Kadowaki et al. 1984; Giorgino et al. 1992). Intracerebroventricular  
administration of low, subdiabetogenic doses of STZ has been shown to induce cognitive (Mayer et al. 
1991; Lannert and Hoyer 1998) and brain cholinergic deficits (Hellweg et al. 1992; Blockland and 
Jolles 1993, 1994), oxidative stress (Sharma and Gupta, 2001a; Sharma and Gupta 2002; Ishrat et al. 
2006; Pathan et al. 2006; Shoham et al., 2006; Kumar et al., 2010; Saxena et al., 2011) as well as 
decrement in brain glucose/energy metabolism (Nitsch and Hoyer 1991; Plaschke et al. 1996; Lannert 
and Hoyer 1998; Hoyer and Lannert 2007), and insulin resistant brain state (Salkovic-Petrisic et al. 
2006; Gruenblatt et al. 2007; Steen 2006; Lester-Coll et al. 2006; Agrawal et al. 2010). These STZ-icv 
induced effects have been extensively reviewed elsewhere (Salkovic-Petrisic and Hoyer, 2007; 
Salkovic-Petrisic et al. 2012), and will not be elaborated here. Recent data on cortical distribution of 
glucose hypometabolism in the STZ-icv treated cynomolgus monkeys (2 mg/kg, on day 1, 7 and 14) 
demonstrated that the distribution pattern was similar to that at early stages of AD patients (Heo et al. 
2011), providing an additional evidence that the effect of STZ-icv treatment is regionally specific and 
species independent. Characterization and validation of the STZ-icv treated animal as a model for 
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sporadic AD has been going on for more than 20 year now, and has not been finished yet. However, 
the important findings on sAD pathophysiology have been already provided by means of STZ-icv 
treated rats which revealed that development of the insulin resistant brain state induced by STZ-icv 
treatment precedes and eventually leads to tau and Aβ pathology, the latter manifested not earlier 
than 3 months following the STZ-icv treatment (Salkovic-Petrisic et al. 2006; Gruenblatt et al. 2007; 
Steen 2006; Lester-Coll et al. 2006; Salkovic-Petrisic et al. 2011; Shingo et al. 2012). These findings 
significantly contributed to the arguments against the hypothesis that β-amyloid pathology is the 
central, primary pathological event in sAD (Reitz 2012) which should also be reflected on the research 
on the novel therapies for sAD and predictive value of the animal models used for this purpose.  
 
STZ-icv animal models have been already used to assess the therapeutic potential of various old and 
novel compounds and drugs, as well as other non-drug therapeutic strategies but their predictivity for 
efficacy in humans has never been assessed. This manuscript aims to review the therapeutic 
strategies that have been tested until now on STZ-icv animal model and evaluate the comparability of 
the drugs’ efficacy in this non-transgenic sAD model in comparison with the results from clinical trials 
on sAD patients (Figure 1). 
 
THERAPEUTIC STRATEGIES TESTED IN STZ-ICV ANIMAL MODELS 
 
Acetylcholinesterase inhibitors and other cholinergic-related drugs 
 
Evidence for a major role of acetylcholine in the pathogenesis of AD has been provided by the 
dramatic decrease in the hippocampus and frontal cortex of choline acetyltransferase (ChAT) (enzyme 
responsible for acetylcholine /ACh/ synthesis) and the marked reduction in cholinergic neuron counts 
in the nucleus basalis in post-mortem studies of AD brains (as reviewed by Greenwald and Davis 
1983). Numerous studies that followed led to the development and, finally, marketing of the inhibitors 
of acetylcholinesterase (AChE) (enzyme responsible for the rapid ACh hydrolysis). It has to be 
emphasized that donepezil, rivastigmine, galantamine and tacrine are the only drugs (with the 
exception of memantine) that have been marketed today for the treatment of the Alzheimer’s disease. 
By blocking the ACh degradation, these drugs prolong its half-live and action on the pre- and post-
synaptic cholinergic receptors. 
 
Supporting the hypothesis that the pathophysiology in the STZ-icv animal models shares huge 
similarities with the one in AD patients, cholinergic deficits have also been consistently found in 
various STZ-icv animal AD models (from newborn and adult rats to adult mice treated with STZ-icv), 
by demonstrating as a decrease in ChAT and an increase in AChE activity in the hippocampus, 
respectively (Hellweg et al. 1992; Blokland and Jolles 1993; Blokland and Jolles 1994; Prickaerts et al. 
1999; Terwel et al. 1995; Sonkusare et al. 2005; Ishrat et al. 2006; (Lester-Coll et al. 2006; de la 
Monte et al. 2006; Kumar et al. 2010; Tota et al. 2011). Importantly, AChE inhibitors tested so far, 
have been consistently successful in improving/preventing memory deficits in STZ-icv sAD models. 
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While until now  galantamine and rivastigmine have not been tested in the STZ-icv models, chronic 
oral administration of donepezil (1 and 3 mg/kg/day) to adult STZ-icv treated rats, dose-dependently 
inhibited AChE activity and improved STZ-icv induced cognitive deficits in memory tests at both doses 
(Sonkusare et al. 2005). These effects were achieved regardless of whether the treatment began 1 
week prior to, in parallel, or 13 days after the STZ-icv administration. In another experiment on mice 
treated STZ-icv with a 1 mg/kg dose who developed severe cognitive deficits 14 days after the STZ-icv 
administration, oral treatment with donepezil or tacrine (5 mg/kg both) one hour prior to the memory 
testing in Passive avoidance and Morris Water Maze tests, caused a significant improvement of the 
memory impairment, associated with a significant decrease in AChE activity (Saxena et al. 2008). 
Additionally, in line with the hypothesis that oxidative stress is a major factor implicated in the 
degeneration of cholinergic neurons in Alzheimer's disease, both donepezil and tacrine suppressed 
STZ-icv-induced oxidative stress by normalizing decreased glutathione (GSH) and increased 
malondialdehyde (MDA) levels (Saxena et al. 2008). Mice treated with 0.1 mg/kg i.p. dose of donepezil 
daily for 15 days (continued during the Morris Water Maze performance days), also demonstrated 
significant cognitive improvement in both acquisition and probe trails, which was accompanied by 
restoration of AChE activity and oxidative stress in the brain (Sharma et al. 2008). This 
neuroprotective effect of AChE inhibitors seen in the STZ-icv animal models is in line with the 
neuroprotective effect of these drugs found in AD patients (Takada et al. 2003; Hashimoto et al. 2005; 
Akasofu et al. 2008). Literature data on cognitive evaluation of disease-modifying efficacy of AChE 
inhibitors in the transgenic mice AD models, which demonstrate age-dependent cognitive decline, are 
available only for galantamine. At age 6 weeks, heterozygous transgenic APP23 mice which were 
subcutaneously implanted with osmotic pumps delivering saline or galantamine (1.3 or 2.6 mg/kg/day) 
for 2 months, showed significantly improved spatial cognition only when treated with a low dose, and 
in the probe trail of Morris Water Maze test (Van Dam and De Deyn 2006). Neither of doses exerted 
the beneficial effects during the training trials and a higher galantamine dose was ineffective in the 
probe trial, suggesting that galantamine might specifically affect certain processes associated with 
consolidation or retrieval of spatial memory. The observed U-shaped dose-response curve is in line 
with the literature data for AChE inhibitors (Braida et al. 1996). 
 
Normalization of the ChAT and AChE activity in the STZ-icv animal models has been found in the 
treatment with some other drugs, associated or not associated with the antioxidative effects. A 
decrease in hippocampal ChAT activity was completely prevented by a 2-week oral treatment of 
acetyl-L-carnitine which acts by enhancing the utilization of alternative energy sources (Prickaerts et 
al. 1995; Terwel et al. 1995). Changes in both ChAT and AChE in the hippocampus were prevented 
by chronic intraperitoneal treatment with the antioxidant coenzyme Q10 (Ishrat et al. 2006). Pre-
treatment with a hepatoprotectant silibinin (100 and 200 mg/kg, po) attenuated STZ-icv (1 mg/kg) 
induced memory impairment by reducing oxidative and nitrosative stress and synaptosomal calcium 
ion level, restored increased activity and mRNA expression of AChE and also significantly increased 
STZ-icv induced decrement in α-7-nAChR mRNA expression in addition to dose-dependent 
restoration of ATP levels (Tota et al. 2011). Oral treatment with p,p'-methoxyl-diphenyl diselenide 
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(/MeOPhSe-2/ 25 mg/kg) was able to reverse the learning and memory impairments in mice induced 
by parallel icv administration of STZ, and to protect against the increase in AChE activity, measured 9 
days following the drug treatments (Pinton et al. 2010). 
 
Beside the antioxidative effects, AChE inhibition could be successfully combined with other effects in 
some multifunctional compounds such as ladostigil (TV3326) which combines the AChE inhibitory 
activity of rivastigmine with the effects of selective monoamine oxidase-B inhibition from rasagiline 
(Weinstock et al. 2001). Chronic oral treatment with ladostigil (75 µmol/kg) almost completely 
prevented the STZ-icv induced memory impairment in rats and additionally reduced the STZ-icv 
induced neuronal damage and accompanied microgliosis in the fornix and corpus callosum. 
Furthermore, daily oral administration of ladostigil (1 or 17 mg/kg) for 1 week, before and after the 
STZ-icv treatment prevented both memory deficits and the glial and oxidative-nitrative stress changes 
in rats (Shoham et al. 2007). No data has been available on ladostigil testing in transgenic mice AD 
models. 
 
NMDA receptor antagonists 
 
Glutamate N-methyl-d-aspartic acid (NMDA) receptor channel antagonist memantine which blocks 
NMDA overstimulation in excitotoxicity (Kornhuber et al. 1989) is the only drug marketed for the 
treatment of AD in addition to the AChE inhibitors. Few animal studies which have been focused on 
the glutamate neurotransmission in the STZ-icv animal models revealed, in general, changes similar to 
those found in AD patients. An increased expression of glutamate transporter mRNA has been found 
previously in the STZ-icv rats (Grünblatt E et al. 2004), and deficits in hippocampal synaptic 
transmission and long-term potentiation (LTP) observed in the STZ-icv treated rats were recently 
suggested to be mainly due to the postsynaptic mechanisms and were accompanied by changes in 
the expression and function of glutamate alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
(AMPA) receptors (Shonesy et al. 2012). Furthermore, LTP deficits were found to correlate with 
decreased expression of NMDA receptor subunits NR2A and NR2B, which could be related to the 
reduction of brain derived neurotrophic factor (BDNF) in the STZ-icv rat model (Shonesy et al. 2012). 
Reduction in hippocampal glutamate NMDA receptor subunits NR1A and NR2B as well as down-
regulation of BDNF have also been found in the brain of sAD patients post mortem (Bi and Sze 2002; 
Connor et al. 1997). In line with these similarities in the pathophysiological background, testing of the 
therapeutic potential of memantine in the STZ-icv rat model revealed that the memory impairment 
induced by 3 mg/kg STZ-icv dose in rats was successfully reversed by a 2-week memantine treatment 
with a 5 mg/kg i.p. dose (Ponce-Lopez et al. 2011). However, the memory functions were tested by 
food magazine and autoshaping training while there is no data on spatial memory in the Morris Water 
Maze test. Glutamate neurotransmission was not investigated in this experiment, but results showed 
that memantine-induced memory restoration in the STZ-icv treated rats was associated with a 
significant recovery of p-GSK3β levels downstream the insulin receptor signalling in the hippocampus 
only, indicating that the drug might have a beneficial effect on the insulin resistant brain state in this 
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model. Considering that decrement of the inactive p-GSK3β form turns the p-GSK3β/GSK3β ratio to 
increased GSK3β activity which results in tau protein hypophosphorylation, this finding in the STZ-icv 
rat model is in line with the finding that memantine reduces tau phosphorylation in sAD patients post 
mortem (Degerman Gunnarsson et al. 2007). Literature data on cognitive evaluation of disease-
modifying efficacy of memantine in the transgenic mice AD models demonstrates that in heterozygous 
transgenic APP23 mice which were, at age 6 weeks, subcutaneously implanted with osmotic pumps 
delivering saline or memantine (7.2 or 14.4 mg/kg/day) for 2 months, memantine dose-dependently 
improved acquisition performance (path length) and spatial accuracy during probe trial of the Morris 
Water Maze trail (Van Dam and De Deyn 2006). Memantine treatment (30 mg/kg/day p.o.) for 2 to 3 
weeks initiated at the age of 8 months also significantly improved the acquisition of the Morris Water 
Maze in APP/PS1 mice AD model without affecting swimming speed although it had no effects on 
locomotor activity or aggressive behaviour (Minkeviciene et al. 2004).   
 
Compounds with predominant antioxidative activity, often accompanied by other 
neuroprotective properties 
 
As already mentioned above, increasing evidence indicates that cholinergic deficits found in AD may 
interact with oxidative stress in a vicious cycle, crucial for the AD patophysiology. Oxidative stress has 
often been emphasized as probably the earliest feature in the AD brain with implications as an 
important mediator in the onset, progression and pathogenesis of the disease (Götz et al., 1994; Zhu 
et al. 2007). The interpretation of the results of clinical trials which tested the therapeutic activity of 
various antioxidants is difficult due to a lack of specificity of such drugs to neural mitochondria where 
ROS production is most significant, and due to the additional activities these drugs may possess such 
as anti-inflammatory and iron-chelating ones (Bonda et al. 2010; Wollen 2010). Many of antioxidant 
drugs have also been tested in the STZ-icv animal sAD models, suitable for such task due to the 
chemical nature of STZ which leads to generation of intracellular free radicals, nitric oxide (NO) and 
hydrogen peroxide, and mitochondrial damage (Szkudelski 2001). In line with that, significant and 
progressive elevation of MDA and decrement of GSH level, respectively, as well as oxidative-nitrative 
stress have been found in the rat brain 1 to 8 weeks following the STZ-icv treatment (Sharma and 
Gupta 2001a; Sharma and Gupta 2002; Ishrat et al 2006; Pathan et al 2006; Shoham et al. 2007; 
Kumar et al. 2010; Saxena et al. 2011), demonstrating resemblance to the oxidative stress condition in 
the human sAD patients post-mortem.  
 
Several potential mitochondrial antioxidant therapies have been tested in the STZ-icv animal models. 
Alpha-lipoic acid (ALA) is a potent free radical scavenger, a powerful antioxidant which also chelates 
metals, reduces inflammation and increases ACh (as reviewed by Wollen 2010).  In the rats treated 
chronically with alpha lipoic acid (50, 100 and 200 mg/kg) orally for 21 days starting from day 1 of STZ 
injection and administered before the STZ injection, a dose-dependent effect of ALA was observed 
(Sharma and Gupta 2003). Only the highest ALA doses significantly improved the STZ-icv induced 
cognitive deficits which correlated with significant reduction in MDA levels only in the high-dosed STZ-
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icv treated rats. Data on ALA efficacy in AD patients suggests its beneficial effects in stopping the 
progressive memory decline and keeping it on the constant level but a small number of patients do not 
allow a firm conclusion yet (Hager et al. 2007).  
 
Acetyl-L-carnitine (ALCAR) works synergistically with ALA to transport acetyl groups and fatty acids 
into the mitochondria for energy production and additionally promotes synthesis of ACh and clearing of 
mitochondria of toxic fatty-acid metabolites, also demonstrating various neuroprotective activities (as 
reviewed by Wollen 2010). Two weeks of oral pre-treatment with ALCAR (75 mg/kg) which readily 
passes the blood-brain barrier, prevented partly the STZ-icv induced effects in rats, as reflected by an 
attenuation of the STZ-icv induced decrease in hippocampal but not the cortical CAT activity, and by 
attenuation of cognitive deficits in the MWM probe but not in the training trials, as well as by 
inefficiency to restore the neuronal septal damage induced by STZ-icv (Terwel et al. 1995). The 
reason of this discrepancy between the low-to-moderate efficacy in STZ-icv animal models and a 
consistent efficacy in AD patients, in whom a meta-analysis of 21 double-blind randomized, placebo-
controlled studies (3-12 months) showed either improvement or delayed progression of cognitive 
decline (Montgomery et al. 2003), is unclear yet, but could be related to the optimisation of the ALCAR 
dose and/or treatment length and initiation, in the STZ-icv rat experiments.  
 
Coenzyme Q10 (CoQ10) naturally resides in the inner mitochondrial membrane and acts to carry the 
high energy electrons in the electron transport chain from complex 1 to complex II during oxidative 
phosphorylation. Recent studies have shown the CoQ10 to be neuroprotective in various conditions but 
mostly in in vitro and in vivo animal models (as reviewed by Bonda et al. 2010, and Wallen 2010), as 
until now the only clinical trial with CoQ10 monotherapy was a double-blind, placebo controlled study 
on AD patients (N=78) treated 16 week with or with 400 mg of CoQ10 3 times/d, in which no effect on 
cognition and cerebrospinal antioxidant biomarkers were found (Galasko et al. 2012). Additionally, a 
synthetic variant of CoQ10, idebenone, has been tested in clinical trials in which inconsistent results 
were obtained; better cognitive score in with 90 -120 mg doses only (Gutzmann et al. 1998; Weyer et 
al. 1997) and no effect with even higher doses in another trial (Thal et al. 2003). Contrary to that, 
neuroprotective effect of CoQ10 was clearly demonstrated both at the cognitive and neurochemical 
level in the STZ-icv rat sAD model (Ishrat et al. 2006).  Supplementation with CoQ10 (10 mg/kg b.w. 
i.p.) for 3 weeks, initiated 24 hours after the STZ-icv injection in rats significantly reversed STZ-icv 
induced cognitive deficits in Passive avoidance and Morris Water Maze tests as well as it reversed all 
changed markers of oxidative stress in the hippocampus and prefrontal cortex (MDA, GSH, glutathion 
peroxidase/reductase, thiobarbituric acid reactive substances), and in addition to already mentioned 
normalization of ChAT and AChE activity in hippocampus (Ishrat et al. 2006). The reason for such a 
discrepancy between the human and animal studies is unclear yet. 
 
Some of the compounds, such as sesamol, nitric oxide synthase inhibitor or organoselenium which 
possess antioxidant activity alone or in combination with cholinergic or anti-inflammatory activities 
observed in vitro and in other animal models, have not been tested in AD randomized clinical trials and 
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in transgenic mice AD models. However, their effects on memory and neurochemical parameters in 
the brain have been explored in the STZ-icv animal sAD model.  
 
Sesamol (5-hydroxy-1,3-benzodioxole or 3,4-methylenedioxyphenol), a potent anti-oxidant and anti-
inflammatory molecule, markedly improved STZ-icv induced cognitive impairment in rats following 21-
day oral treatment with 4 or 8 mg/kg dose (Misra et al. 2011). In addition to reducing brain AChE 
activity and serum tumor necrosis factor (TNF)-α levels, it also attenuated oxidative-nitrite stress in the 
brain of STZ-icv treated rats. Cognitive impairment and oxidative-nitrite stress in the STZ-icv treated 
rats were also restored by a non-specific nitric oxide synthase (NOS) inhibitor, L-N
G
-Nitroarginine 
methyl ester (L-NAME) (10 mg/kg i.p.), 21-day treatment alone, while its combination with sub-
effective dose of sesamol (4 mg/kg) potentiated its protective effect (Misra et al. 2011), confirming that 
modulation of nitrite signalling and the oxide-inflammatory cascade might provide therapeutic effects in 
an AD condition. 
 
Selenium (Se), a nutritionally essential trace element with known antioxidant potential, protects the 
brain from oxidative damage in various models of neurodegeneration As already mentioned, 
neuroprotective effect of organoselenium (MeOPhSe)(2) administered orally (25 mg/kg) 30 min prior to 
STZ-icv injection in mice was manifested in cognitive improvement in the Y-maze test associated with 
an anticholinesterase efficacy (Pinton et al. 2010) but additional experiments demonstrated that its 
neuroprotection in the STZ-icv model is due to its antioxidant activity as well (Pinton et al. 2011). Pre-
treatment supplementation with sodium selenite, a salt of Se (0.1 mg/kg p.o. for 7 days) significantly 
improved learning and memory ability in Passive avoidance and Morris Water Maze tests in the STZ-
icv treated rats (Ishrat et al. 2009). This supplementation also significantly ameliorated all oxidative 
stress-related alterations in GSH, TBARS and glutathion peroxidase/reductase in the hippocampus 
and cerebral cortex, and additionally significantly restored ATP levels as well as ChAT activity in the 
hippocampus.  
 
Considerable attention has been focused on increasing the internal antioxidant defences in response 
to AD, and in line with that, the role of vitamin E well known as an antioxidant drug. AD patients were 
found to have significantly low cerebrospinal and serum vitamin E concentrations which increased 
(123% and 145%, respectively) following the vitamin E supplementation (400 IU/day, 1 month) 
(Jimenez-Jimenez et al., 1997, Kontusch and Schekatolina, 2004). In a placebo-controlled trial, 
vitamin E (2000 IU/day, 2 years) alone slowed (-53%) functional deterioration in patients with 
moderate AD while in combination with vitamin C it reduced prevalence (-78%) and incidence (-64%) 
of AD (Kontusch and Schekatolina, 2004). However, recent double-blind, placebo controlled study on 
AD patients (N=78) treated 16 week with a combination of 800 IU/d of vitamin E plus 500 mg/d of 
vitamin C plus 900 mg/d of α-lipoic acid (E/C/ALA) demonstrated that E/C/ALA treatment combination 
accelerated the cognitive decline although the cerebrospinal fluid F-2-isoprostane levels, which 
represented the oxidative stress biomarker, decreased by 19% from baseline (Galasko et al. 2012). 
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Whether combination with ALA or some other factors have been responsible for this unfavourable 
effect on cognition remains to be determined.  
 
Contrary to the conflicting results in human studies, experiments with vitamin E treatment of the STZ-
icv rats give more consistent results suggesting its neuroprotective effects in the experimental sAD. 
Rats pre-treated with vitamin E (100 mg/kg i.p. once daily for 3 weeks) and afterwards injected icv with 
STZ (3 mg/kg) demonstrated significantly better cognitive performance in Passive avoidance and 
Morris Water Maze tests performed 2 weeks after the STZ-icv treatment (Ishrat et al. 2009). Moreover, 
pre-treatment with vitamin E demonstrated antioxidant activity, observed as significantly enhanced 
GSH level and decreased level of thiobarbituric acid reactive substances (TBARS), associated with 
significant restoration of CAT activity in the hippocampus. These findings have been confirmed in 
another experiment which explored the effect of both isoforms of vitamin E, alpha-tocopherol and 
tocotrienol against STZ-icv induced cognitive impairment and oxidative-nitrosative stress in rats 
measured 3 weeks following the STZ-icv treatments (Tiwari et al. 2009). Alpha-tocopherol as well as 
tocotrienol treated STZ-icv groups showed significantly less cognitive impairment in Morris Water 
Maze and Elevated plus maze tests but the effect was more potent with tocotrienol. In line with that, 
both isoforms of vitamin E effectively attenuated the reduction in GSH and catalase and reduced the 
MDA and nitrite levels as well as AChE activity in the brains of STZ-icv treated rats in a dose-
dependent manner. These results, which provide evidence for the difference in efficacy between the 
different vitamin E isoforms in the STZ-icv rat sAD model, actually support the recent hypothesis that 
conflicting results in human AD studies might be related to the different vitamin E isoform used (Wollen 
2010). 
 
In vitro and in vivo animal studies suggest potentially important role for diet in the causation and/or 
prevention of sAD. Causation could be related to the reduced levels of endogenous antioxidants like 
the above mentioned vitamin E, while prevention could refer to the antioxidant potential of 
polyphenolic compounds obtained from dietary sources, such as resveratrol from grapes and peanuts 
and curcumin from turmeric (plant of the ginger family). These compounds have been found to 
additionally possess anti-inflammatory as well as anti-amyloidogenic activity due to therapeutic 
potential of resveratrol and curcumin has been explored in AD clinical trials (Wallen 2010). 
Resveratrol is found in red wine and although several clinical studies suggested that moderate to mild 
red wine consumption was associated with a low risk of AD, this notion is still controversial and 
remains to be clearly demonstrated (as reviewed by Vingtdeux et al. 2008). Polyphenols have potent 
anti-amyloidogenic and anti-fibril effects in vitro, suggesting that resveratrol may prevent the formation 
of toxic Aβ oligomers and protofibrillar intermediates (Riviere et al. 2008). Moderate consumption of 
red wine lowered Aβ levels and the associated neuropathology in Tg2576 AD mouse model (Wang et 
al. 2006). Anti-amyloidogenic potential of resveratrol has not been explored in the STZ-icv rat sAD 
model but chronic treatment with trans resveratrol (10 and 20 mg/kg, i.p. for 21 days) starting from day 
1 of STZ-icv injection significantly prevented STZ-icv induced cognitive impairment and oxidative 
stress manifested as increased brain GSH levels (Sharma and Gupta 2002). 
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Curcumin has been demonstrated to have a beneficial role in neurodegenerative disorders due to its 
various neuroprotective properties as in addition to antioxidant, anti-inflammatory and anti-
amyloidogenic effects, curcumin possesses also copper and iron chelating activity (Baum and Ng 
2004). However, clinical studies face the problem of its low bioavailability because of a hydrophobic 
nature and have revealed no cognitive benefit relative to placebo in AD patients (as reviewed by 
Wallen 2010). In spite of that, wildly used turmeric spice (curcumin) in India has been suggested to be 
responsible for a much lower incidence of AD in India than the United States. In vivo studies in AD 
transgenic mice models have shown that dietary curcumin can cross the blood-brain barrier and 
significantly decrease Aβ deposition and plaque burden as well as markedly inhibit tau 
phosphorylation (Wang et al. 2009; Ma et al. 2009). The effect of curcumin has been extensively 
investigated in the STZ-icv animal models. Administration of curcumin (200 mg/kg, po) both 
continuously from 1
st
 - 14
th
 day and from 14
th
 - 20
th
 post STZ-icv treatment significantly restored the 
memory deficit and insulin receptor protein level in the hippocampus and cerebral cortex of the STZ-
icv treated rats (Agrawal et al. 2010). Curcumin pre- and post-treatment additionally normalized AChE 
levels in both regions and attenuated STZ-icv induced oxidative stress by restoring MDA and GSH 
levels. The results suggest that besides the anticholinesterase and antioxidant activity, an effect on 
brain IR may also be an important factor for protective effect of curcumin against STZ induced sAD 
model. Similar curcumin-induced (80 mg/kg for 3 weeks) antioxidant and cholinergic effect as well as 
prevention of the cognitive deficits in the STZ-icv rat model have been observed by others (Ishrat et al. 
2009). Additionally, curcumin dose-dependently (10, 20, 50 mg/kg per os for 21 days, starting from the 
day of STZ-icv injection, or 20 and 50 mg/kg for 7 days initiated from 19
th
 – 25
th
 day post STZ-icv 
treatment) improved cerebral blood flow in STZ-icv treated mice (Awasthi et al. 2010). In another 
experiment, treatment with curcumin (300 mg/kg i.p. for 10 days) initiated from the 25th day after STZ-
icv injection led to cognitive improvement associated with restoration of the STZ-icv induced 
decrement in insulin growth factor (IGF)-1 in the brain as well as to the reduced neuronal loss (Isik et 
al. 2009). Furthermore, the noted beneficial effect of curcumin (20 mg/kg per os for 14 days) on STZ-
induced dementia in mice was significantly abolished by pre-treatment with PPAR-gamma receptor 
antagonist bisphenol-A-diglycidyl ether, i.e., BADGE (30 mg/kg i.p.), suggesting that its beneficial 
effects might be also mediated through the activation of PPAR-gamma receptors (Rinwa et al. 2010). 
 
Daily treatment with a naturally occurring flavonoid quercetin (2.5, 5 and 10mg/kg, p.o. for 21 days) 
starting from the first icv dose of STZ to mice, prevented STZ-induced memory impairment as 
assessed by Morris Water Maze and passive avoidance tests and showed a dose-dependent 
restoration of cerebral blood flow and ATP content (Tota et al. 2010). Quercetin decreased oxidative 
and nitrosative stress as evidenced by a significant decrease in MDA, nitrite and increase in GSH 
levels, and additionally attenuated elevated AChE activity in the STZ-treated mice.  
 
Recent evidence indicates that rutin (the glycoside between the quercetin and the disaccharide 
rutinose), exhibits antioxidant potential and has neuroprotective effects. Rutin pre-treatment (25 
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mg/kg, orally, once daily for 3 weeks) significantly improved impaired memory and significantly 
attenuated TBARS activity of poly ADP-ribosyl polymerase, and nitrite level and decreased GSH level 
and catalase activity in the hippocampus of STZ-icv rats, as measured two weeks following the icv 
treatment (Javed et al. 2012). These effects were also accompanied by anti-inflammatory activity 
reflected as the reduced expression of cyclooxygenase-2 (COX-2), interleukin-8 (IL-8) and inducible 
NOS. 
 
Melatonin is a naturally occurring hormone which is produced in decreasing amounts with age, and is 
also a powerful antioxidant. Literature data suggests that melatonin provides mitochondrial support, 
acts anti-amyloidogenic and neuroprotective also against tau tangles, but  few clinical studies have 
examined its effect on AD, and those that did were small and of poor quality (as reviewed by Wallen 
2010). Administration of melatonin (2.5, 5.0 and 10mg/kg, i.p.), started 1h prior to 1st icv dose of STZ 
and continued up to 14 days, significantly attenuated the effect of STZ-induced oxidative stress (GSH 
and MDA levels) and histopathological changes (damaged periventricular cells and damaged cells in 
the hippocampal CA4 region) in STZ-icv treated mice, but cognitive deficits, measured by MWM, were 
attenuated only by the highest dose (Saxena et al. 2010). In line with the pathophysiological finding of 
mitochondrial dysfunction in AD, the effects of melatonin on brain mitochondrial function were explored 
in APP/PS1 transgenic mice AD model treated for 1 month with melatonin (Dragicevic et al. 2011). 
Subsequent in vitro analysis revealed that melatonin treatment decreased mitochondrial Aβ levels by 
two- to fourfold in different brain regions which was accompanied by a near complete restoration of 
mitochondrial respiratory rates, membrane potential, and ATP levels in isolated mitochondria from the 
hippocampus, cortex, or striatum.  
 
As already mentioned, some drugs which have completely different indication have been found 
potentially therapeutic in dementia treatment due to the variety of their neuroprotective effects 
demonstrated in the non-clinical studies. Erythropoietin, a glycoprotein hormone that controls 
erythropoiesis, has been tested in the STZ-icv mice model where the post-treatment with doses of 500 
and 1,000 IU/Kg i.p., significantly reversed streptozotocin-induced learning and memory deficits along 
with attenuation of oxidative stress (TBARS and GSH levels) and restoration of brain AChE activity in 
the brain (Kumar et al. 2010). Similar to that, the antioxidative effect of the HIV protease inhibitor 
indinavir (100 and 200 mg/kg p.o. for 15 days) accompanied by AChE activity restoration and 
cognitive improvement in the Morris Water Maze test has been observed in the STZ-icv treated mice 
(Sharma et al. 2008). This effect has been associated with the findings that HIV protease has 
structural homology to beta-secretase 1 (BACE) (Hong et al. 2000) and thus can modulate BACE 
activity, and consequently, possibly, the amount of amyloid-β formation (Nunan and Small 2000). 
Cyclic nucleotides cGMP and cAMP are known to play an important role in learning and memory 
processes. Enhancement of cyclic nucleotide signalling by phosphodiesterase inhibitors (PDE) has 
been reported to be beneficial in several neurodegenerative disorders associated with cognitive 
decline. The STZ-icv treated rats, which were administered PDE 4 inhibitor RO-20-1724 (125, 250 and 
500 µg/kg i.p.) for 21 days following the first i.c.v. STZ administration, demonstrated significant, dose-
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dependent attenuation of the STZ-icv induced cognitive deficits (measured by Passive avoidance and 
Morris Water Maze tests) and oxidative stress (measured by GSH, MDA and nitrite levels), as well as 
restoration of the AChE activity (Sharma et al. 2012). Chronic treatment with vinpocetine, a PDE 1 
inhibitor (5, 10 and 20 mg/kg i.p.), for 21 days following first STZ-icv injection accomplished similar, 
dose-dependent beneficial effects on memory, oxidative stress and AChE activity in the brain of STZ-
icv treated rats (Deshmukh et al. 2009). Hippocampal alterations, manifested as astroglial activation 
(S100B accumulation which was independent of the significant alteration in glial fibrillary acid protein), 
nitrative stress and glycation, found in the STZ-icv treated rats 2 weeks after the icv treatment were 
prevented by aminoguanidine (100 mg/kg i.p., given after the STZ-icv injection on days 2 and 4), as 
well as cognitive deficits (Rodrigeus et al. 2009). 
 
A number of different Chinese and Indian medicinal plants have been demonstrated to exhibit 
protective effects on the STZ-icv induced memory deficits, for which various underlying mechanism, 
including antioxidant and anti-AChE activity, were suggested (to mention only few; Hou et al. 2012; 
Veerendra Kumar and Gupta 2003; Saxena et al. 2007; Diwu et al. 2011). However, the extensive 
review of these plants and their effects is beyond the scope of this manuscript.   
 
The standardized extract EGb 761 from the dried green leaves of Ginkgo biloba is a complex mixture 
of ingredients with a uniquely broad spectrum of pharmacological activities on the central nervous 
system. Ginko biloba contains compounds that have antioxidant and anti-inflammatory properties. 
Although a quite a number of trials has been conducted with Ginkgo biloba in demented patients, a 
Cochrane review of 36 clinical trials concluded that the effect of Ginkgo biloba is inconsistent and that 
further studies are needed to elucidate its role in AD (Birks et al. 2009). STZ-icv animal models 
demonstrated that Ginkgo biloba is only partly effective in restoring the cognitive deficits while in 
transgenic mice models, Ginkgo biloba successfully normalized memory impairment. Animal studies 
on Ginkgo extracts showed that the ongoing deterioration in behaviour and the maintained deficit in 
cerebral energy metabolism occurring after a triplicate i.c.v. STZ injection were significantly slowed 
down by EGb761 treatment  (50 mg/day/rat in food pellets for 12 weeks) (Hoyer et al. 1999). The 
deficits in learning, memory and cognition were partially compensated, and the disturbances in 
cerebral energy metabolism returned to almost completely normal values. Additional experiment on 
this model revealed that EGb761 treatment (25 g/day/rat in food pellets) normalized the STZ-icv 
induced increase in glucose transporter (GLUT) 3 expression and partially compensated the STZ-
mediated enhancements in hippocampal insulin receptor binding (Löffler et al. 2001). Six-month 
treatment with Ginkgo biloba (70 mg/kg/day in drinking water), initiated at age of 8 month, can block 
an age-dependent decline in spatial cognition without altering Aβ levels and without suppressing 
protein oxidation in a transgenicTg2576 mouse model of AD (Stackman et al. 2003). 
 
Considering the important role of iron as a mediator of oxidative stress in AD (Castellani et al. 2012), 
compounds the exhibit iron-chelating activity are of a particular interest in search for the effective AD 
therapy. One such compound is a multifunctional, brain permeable iron chelating agent M30 [5-(N-
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methyl-N-propargyaminomethyl)-8-hydroxyquinoline], which possesses the neuroprotective N-
propargyl moiety of the anti-Parkinsonian drug, monoamine oxidase (MAO)-B inhibitor, rasagiline and 
the antioxidant-iron chelator moiety of an 8-hydroxyquinoline derivative of the iron chelator, VK28 
(Youdim et al. 2005). Assessment of therapeutical potential of M30 is currently at the preclinical level 
at which it has demonstrated neuroprotective activity in vitro and in vivo in animal models of 
neurodegenerative disorders as well as in reversal of age-associated memory impairment (Youdim 
2012; Kupershmidt et al. 2011, 2012a). Systemic treatment of APP/PS1 Tg mice with M30 for 9 
months significantly attenuated cognitive impairments in a variety of tasks of spatial learning and 
memory retention, working memory, learning abilities, anxiety levels, and memory for novel food and 
nesting behaviour (Kupershmidt et al. 2012b). These beneficial effects of M30 on cognition were 
associated with reduced cerebral iron accumulation and a marked decrease in cerebral Aβ levels and 
plaques and phospho-tau levels, and on the signalling level, with marked down-regulation of 
phosphorylated cyclin-dependent kinase 5 and increased protein kinase B and glycogen synthase 
kinase 3β phosphorylation. The latter suggests that restoration of dysfunctional brain insulin signalling 
might underlie neuroprotective activity of M30 in the AD condition. Therapeutical potential of M30 in 
the STZ-icv rat model is currently under investigation in our lab and preliminary results suggest that 
both M30 high-dose pre-treatment and post-treatment prevents and improves cognitive deficits, 
respectively (unpublished observation). 
 
Drugs with predominant anti-inflammatory activity 
 
Epidemiologic evidence suggests that non-steroidal anti-inflammatory drugs (NSAIDs) delay onset of 
Alzheimer's dementia (AD), but randomized trials show no benefit from NSAIDs in patients with 
symptomatic AD (reviewed by Wollen 2010). The results of a recent Alzheimer's Disease Anti-
inflammatory Prevention Trial (ADAPT) which randomized 2,528 elderly persons to naproxen or 
celecoxib versus placebo for 2 years + 2-year extension period, suggest a revision of the original 
ADAPT hypothesis that NSAIDs reduce AD risk (Breitner et al. 2011). In line with these results, 
NSAIDs have an adverse effect in later stages of AD pathogenesis, whereas asymptomatic individuals 
treated with conventional NSAIDs such as naproxen experience reduced AD incidence, but only after 
2 to 3 years. Thus, treatment effects seem to differ at various stages of the disease. However, based 
on the recent analysis of 604 potentially relevant studies carried out in AD patients population so far, 
the conclusion of the Cochran review is that efficacy of aspirin, steroid and NSAIDs (traditional 
NSAIDs and COX-2 inhibitors) is not proven and due to these drugs cannot be recommended for the 
treatment of AD (Jaturapatporn et al. 2012). Considering the animal AD models, the effect of NSADIs 
has been investigated in genetically modified mice models and in the STZ-icv rat model, however 
conflicting results have been obtained. Overexpression of COX-2 in APPswe-PS1dE9 mice AD model 
resulted in specific deficits in spatial working memory in female but not male mice and these sex-
specific deficits were abolished by pharmacological inhibition of COX-2 by celecoxibe, in the absence 
of significant changes in amyloid burden (Melnikova et al. 2006). Data indicates that COX-2 activity 
promotes cognitive deficits in a sex-dependent but amyloid burden-independent manner in this mice 
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AD model. Similar lack of amyloid burden-clearing activity of celecoxib (and ibuprofen) has been found 
in APP/PS1 transgenic mice AD model in which COX-1 preferring inhibitor flurbiprofen administered in 
a diet, dramatically reduced amyloid plaque and nonfibrillar deposit burden (Jantzen et al. 2002). In 
the experiment on STZ-icv rat model, selective inhibitors of COX-1 (valeryl salicylate, 5 and 10 
mg/kg), COX-2 (etoricoxib, 5 and 10 mg/kg) or COX-3 (phenacetin, 20 and 40 mg/kg) were 
administered daily for 21 days, intraperitoneally (Dhull et al. 2012a). In comparison with the control 
animals, COX-1 and COX-2 inhibitors significantly increased the survival of hippocampus CA1 
neurons in the STZ-icv treated rats in a dose dependent manner while COX-3 inhibitor had no effect, 
suggesting the differential role of COX isoenzymes in neuronal death in hippocampal CA1 regions in 
the STZ-icv rat sAD model. In the same experimental design, COX-1 and COX-2 inhibitors significantly 
improved STZ-induced cognitive impairment, increased the survival of pyramidal neurons, and 
restored oxidative stress biomarkers (GSH, MDA, nitrite levels, SOD), while COX-3 inhibitor failed to 
restore the cognitive performances and oxidative stress condition, and had no effect on neuronal 
survival (Dhull et al. 2012b. However, in the experiment of Sharma and co-workers (2008), celecoxib 
treatment (100 mg/kg i.p. for 5 days and continued for 5 days during the cognitive testing) was used to 
induce experimental dementia in rats, for which authors concluded that it might be attributed to the 
stimulatory effect of celecoxibe on amyloid beta-42, and on brain AChE activity, as well as on oxidative 
stress. In fact celecoxibe-induced dementia, oxidative stress and AChE activity were comparable to 
those induced by STZ-icv treatment of (Sharma et al. 2008). The reason for such a contradictory effect 
of celecoxibe in the two experiments of Dhull and co-workers (2012a; 2012b) and the experiment of 
Sharma and co-workers (2008) is unclear and should be further investigated. 
 
NSAIDs treatment in transgenic mice AD models have generally led to a conclusion that adequate 
doses of traditional NSAIDs, or their nitrate esters, reduce the amyloid burden and levels of 
neuroinflammation, as reviewed elsewhere (McGeer et al. 2007). An acute 7 day oral treatment of 10-
month-old transgenic APPV717I mice with ibuprofen resulted in decreased beta-secretase-1 (BACE1) 
mRNA and protein levels, and reduction in the number of activated microglia and reactive astrocytes in 
the hippocampus and cortex, accompanied by reduction in the expression of the proinflammatory 
enzymes COX2 and inducible NOS (Heneka et al. 2005). Treatment of 11-month-old Tg2576 mice 
with ibuprofen for 16 weeks resulted in the dramatic and selective reduction of soluble Aβ42 and 60% 
amyloid plaque load in the cortex (Yan et al. 2003). However, studies that tested the effects of 
celecoxibe in the transgenic mice AD models showed that it either failed to reduce the inflammatory 
burden (higher dose) or actually increased the levels of Aβ42 (lower dose) (McGeer et al. 2007). 
 
Insulin-sensitizing and other anti-diabetic drugs 
 
Epidemiological studies have provided direct evidence that diabetes mellitus (DM) type 2 is a strong 
risk factor for AD (as reviewed by Takeda et al. 2011) and insulin resistant state has been recognized 
to play an important role in the pathophysiology of the sporadic AD form (Bosco et al. 2011). In line 
with that, insulin-sensitizing agents such as peroxisome-proliferator activated receptor (PPAR) 
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agonists which also demonstrate anti-inflammatory activity, have been tested for their therapeutic 
potential in clinical trials and in animal experiments. Six-month pioglitazone (PPAR γ/α agonist) daily 
treatment of a small number of patients with mild AD accompanied with DM type II improved their 
cognition and regional cerebral blood flow in the parietal lobe in addition to decrement in fasting 
plasma insulin levels (Sato et al. 2011). In a small number of AD non-diabetic patients, 18-month 
treatment with pioglitazone (45 mg/day) as add-on therapy to the AChE inhibitors produced no 
significant treatment effect on cognition (Geldmacher et al. 2011). Regardless the APOE status, no 
evidence of statistically or clinically significant efficacy in cognition or global function was detected for 
2 mg or 8 mg rosiglitazone-extended release formulation (PPAR γ agonist) as adjunctive therapy to 
ongoing AChEIs in the two clinical phase III studies on AD patients (Harrington et al. 2010; 
Tzimopoulou et al. 2010). 
 
In the STZ-icv animal models, therapeutical potential of pioglitazone (but not that of rosiglitazone) has 
been explored. Memory impairment induced by 3 mg/kg STZ-icv dose in rats was successfully 
reversed by a 2-week oral pioglitazone treatment (30 mg/kg) in the food magazine and autoshaping 
training, which was accompanied by restoration of p-GSK3β levels downstream the insulin receptor 
signalling in the hippocampus but not in the prefrontal cortex (Ponce-Lopez et al. 2011). In another 
experiments, oral pioglitazone (10 and 30 mg/kg, or 20 mg/kg) administration for 14 days, starting 5 
days prior to STZ-icv injection in rats improved cognitive performance in Passive avoidance and Morris 
Water Maze test, which was accompanied by lowered oxidative stress (GSH and MDA levels) and 
improved cerebral glucose utilization (Pathan et al. 2006; Kaur et al. 2009). Additionally, pioglitazone 
treatment of STZ-icv mice significantly attenuated higher levels of brain AChE activity, and oxidative 
stress levels measured by TBARS and GSH. All these beneficial effects of pioglitazone were 
significantly abolished by pre-treatment of nitric oxide synthase inhibitor L-NAME (3 mg/kg i.p.). 
Therefore, results on animal STZ-icv models suggest that pioglitazone neuroprotective effects in AD 
condition may involve central insulin, cholinergic, oxidative and NO pathways.  
 
The PPAR agonist-induced effect has been explored also in the 3-day-old rat pups given STZ-icv 
injection (40 µg/kg) and on the same day treated with a single ip injection of saline or PPAR α/δ/γ 
agonists with memory evaluation and brain analysis being done 4 weeks after the drug treatment (de 
la Monte et al. 2006). PPAR agonist treatments showed responses in range from being inefficient to 
partially or completely rescuing the brains from STZ-mediated neurodegeneration. Regarding the 
beneficial effects, PPAR agonists increased the brain size, preserved insulin and insulin growth factor 
(IGF)-II receptor expressing neurons and IR signalling, also decreased phospho/total tau protein ratio 
and APP mRNA expression, additionally increased ChAT expression and decreased the level of 
oxidative stress. The effects were consistently demonstrating region- and PPAR inhibitor type-
dependency, with PPAR δ agonist, generally, demonstrating the best efficacy than (de la Monte et al. 
2006).  
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The effect of both pioglitazone and rosiglitazone has been extensively investigated in the transgenic 
mice AD models with results not completely comparable to those obtained in the STZ-icv models. In 
the experiment on APP tg mice, pioglitazone counteracted cerebral oxidative stress, glial activation, 
and, partly, cholinergic denervation and completely normalized the cerebral blood flow and glucose 
uptake responses to increased neuronal activity, but it failed to improve spatial memory (Nicolakakis et 
al. 2008). An acute 7 day oral pioglitazone treatment of 10-month-old APPV717I mice attenuated 
astrogliosis in the hippocampus and cortex and reduced the level of soluble Abeta1-42 peptide, in 
addition to reduction of the expression of the proinflammatory enzymes COX2 and inducible NOS, and 
decrement of beta-secretase-1 (BACE1) mRNA and protein levels (Heneka et al. 2005). Cognitive 
performance was not measured. Pioglitazone treatment of Tg2576 mice reduced Ab40 levels but the 
effect on memory function was not reported (Yan et al. 2003). Chronic treatment with rosiglitazone (5 
mg/kg/day) facilitated Aβ clearance and reduced Aβ burden in the hippocampus and entorhinal cortex 
of 13-month-old transgenic (human APP-overexpressing) mice and reduced the expression of 
proinflammatory markers (Escribano et al. 2010). Interestingly, 4 weeks of rosiglitazone treatment in 
this experiment were not enough to restore the hippocampal function for an accurate performance in 
the Morris Water Maze test but all cognitive deficits were normalized following the 16 week-treatment. 
Chronic rosiglitazone treatment in transgenic APP/PS1 and Tg2576 mice also reduced Aβ aggregates 
and Aβ oligomers in addition to restoration of spatial memory impairment (Toledo and Inestrosa 2010; 
Pedersen et al. 2006). These effects were accompanied by attenuated reduction of IDE mRNA in the 
hippocampus (and not in the frontal cortex) of Tg2576 mice.  
 
It is hard to explain why the results on pioglitazone are not completely comparable between the 
transgenic mice and STZ-icv animal AD models and why PPAR  agonists do not exert such a 
beneficial effect in clinical trials. Therefore, further research is needed to elucidate this inconsistency. 
 
Fourteen days following STZ-icv injection, rats treated with twice-daily exedine-4 (Ex-4), a long-acting 
glucagon-like peptide-1 (GLP-1) receptor agonist, had better learning and memory performance in 
the Morris Water Maze test compared with rats treated with saline (Chen et al. 2011). Additionally, 
histopathological evaluation confirmed the protective effects of Ex-4 treatment on hippocampal 
neurons against degeneration, and its reversal effect on tau hyperphosphorylation through 
downregulation of GSK-3β activity. The experiment on STZ-icv treated rats indicated that treatment 
with (Val(8))GLP-1 (50 µM in 10 µl i.c.v.), might prevent age-related neurodegenerative changes by 
preventing decline of learning and memory formation, reduction of phosphorylated tau levels and 
protection of subcellular structures and morphology of neurons (Li et al. 2012). GLP-1 receptor 
agonists have not been yet studied in AD clinical trials.  
 
GSK-3 inhibitors 
 
GSK-3, and particularly GSK-3β isoform, is a key enzyme downstream the insulin receptor signalling, 
dysfunction of which has been well recognized now both in human and animal AD condition. 
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Dysfunction of the insulin receptor signalling cascade in the brain activates GSK-3β which 
consequently may lead to tau protein hyperphosphorylation, a prerequisite for neurofibrillary tangle 
formation. Drugs which modulate GSK-3β activity, like lithium, have been considered as a potential 
therapeutic strategy in AD condition (Medina and Avila, 2010). Although no benefits were obtained 
from short-term lithium treatment in a recent clinical study in AD patients (Hampel et al. 2009), in the 
long-term (12 months) trial in people with amnestic mild cognitive impairment, better performance on 
the cognitive ADAS subscale and in attention tasks associated with a significant decrease in 
cerebrospinal fluid concentrations of phospho-tau, were found in patients treated with lithium (Fortenza 
et al. 2011). 
 
There is only one literature report on lithium treatment in the STZ-icv animal models, in which 
memory impairment induced by 3 mg/kg STZ-icv dose in rats was successfully reversed by a 2-week 
lithium treatment with a 100 mg/kg i.p. dose (Ponce-Lopez et al. 2011). However, the memory 
functions were tested by food magazine and autoshaping training while there is no data on spatial 
memory in the Morris Water Maze test. The results showed that lithium-induced memory restoration in 
the STZ-icv treated rats was associated with a significant recovery of p-GSK3β levels downstream the 
insulin receptor signalling in the hippocampus but not in the prefrontal cortex, indicating that the drug 
might have a beneficial effect on the insulin resistant brain state in this model. Lithium treatment in a 
double transgenic APP/PSEN1mouse model reduced spatial memory impairment and amyloid burden 
as well as astrogliosis, and additionally activated Wnt signalling by the increase in beta-catenin and by 
the inhibition of the GSK-3β (Toledo and Inestrosa 2010). Chronic lithium treatment in aged double 
transgenic mice (AβPPSwe/PS1A246E) decreased the γ-cleavage of amyloid-β protein precursor, 
further reduced amyloid-β production and senile plaque formation, accompanied by the improvement 
in spatial learning and memory abilities (Zhang et al. 2011).  
 
Estrogens replacement therapy 
 
Estrogens depletion in postmenopausal women is a significant risk factor for AD development and the 
potential of estrogen-based hormone therapy (alone or in combination with progesterone) to reduce 
this risk has been widely investigated with controversial results. The recently released Women's 
Health Initiative Memory Study has dampened any enthusiasm for the use of hormonal replacement 
therapy in women to prevent or delay the onset of AD, confirming the previous clinical data that 
estrogen plus progestin therapy increased the risk for probable dementia in postmenopausal women 
aged 65 years or older and additionally did not prevent mild cognitive impairment in these women 
(Shumaker et al. 2003; Mulnard et al. 2000). The effect of estrogens has not been extensively 
investigated in the STZ-icv animal AD models and insufficient data exists for a firm conclusion. 
Estradiol-17beta treatment (200 µg/rat sc, during cognitive testing period) slowed down the STZ-icv 
induced deterioration in memory functions, partially compensated the learning deficit, and improved 
the disturbances in cerebral energy metabolism to the extent that it was almost completely normal 
again (Lannert et al. 1998). Similar beneficial effect of estradiol-17beta monotreatment on cognition 
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has been found in transgenic mice AD model (Levin-Allerhand et al. 2002). Ovariectomy-induced 
depletion of sex steroid hormones in adult female 3xTg-AD mice significantly increased Aβ 
accumulation and worsened memory performance, and estrogen, but not progesterone (alone or 
combined with estrogen) treatment, prevented these effects (Carroll et al. 2007). 
 
Antihypertensive drugs 
 
Cardiovascular pathology appears to have a major impact in cognitive decline and antihypertensive 
drugs of various mechanisms of action, have potential in AD therapy (as reviewed by Wollen 2010). 
Aside from its vasoactive actions, brain renin-angiotensin system has also been implicated in the 
pathogenesis of cognitive decline, and beneficial effects of drugs affecting it are suggested in AD 
condition. In line with that, a recent study confirmed that angiotensin converting enzyme (ACE) 
inhibitors slow the progression of AD (Hajjar et al. 2008). Proposed possible mechanisms of this 
beneficial effect were suggested to include reduction of angiotensin II which reduces acetylcholine 
(leading to AChE increment) and increment in enzyme that breaks down β-amyloid (Wollen 2010). 
Similar beneficial effects in reducing the incidence and/or AD progression, has been found in a clinical 
trial with angiotensin 1 (AT-1) receptor blocker (Li et al. 2010). Although experiments in animal AD 
models are limited, the results support the findings from clinical trials. 
 
When ACE inhibitor perindopril, was given for 21 days to STZ-icv treated rats, it dose dependently 
improved memory by increasing energy metabolism and cerebral blood flow, and additionally 
decreased oxidative and nitrosative stress, activity and mRNA expression of AChE and ACE, as well 
as it mitigated neurodegeneration in STZ treated rat (Tota et al. 2012). Similar effects were found in 
transgenic mice AD models. Perindopril, without affecting brain Aβ deposition, significantly suppressed 
the increase in hippocampal AChE activity and improved cognition in PS2APP-transgenic mice 
overexpressing Aβ in the brain, which was associated with the suppression of hippocampal astrocyte 
activation and attenuation of superoxide (Dong et al. 2011). 
 
AT-1 receptor antagonist candesartan (0.05 mg/kg and 0.1 mg/kg, i.p.) given for 14 days following 
STZ-icv injection to mice, significantly improved latency period in passive avoidance test, and spatial 
memory in water maze test, but only in higher dose (Tota et al. 2009). Treatment with higher (0.1 
mg/kg) dose of candesartan decreased oxidative stress (MDA and GSH) and free radicals, and 
restored increased AChE activity (Tota et al. 2009). Intranasal treatment of the APP/PS1 transgenic 
mouse AD model of AD with losartan, angiotensin II receptor antagonist (10 mg/kg every other day for 
2 months), using at a dosage far below its systemic antihypertensive dose, exerted direct 
neuroprotective effects via its Aβ-reducing and anti-inflammatory effects in the central nervous system 
(Danielyan et al. 2011). Cognitive functions have not been measured. 
 
Chronic administration of a cardial beta blocker carvedilol (1 and 2 mg/kg, i.p.) for a period of 25 
days starting 4 days before STZ-icv administration resulted in an improvement in memory retention, 
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and attenuation of oxidative damage and AChE activity, suggesting carvedilol may have potential in 
the treatment of neurodegenerative diseases. (Prakash and Kumar 2009). Although memory function 
was not measured, carvedilol re-established basal synaptic transmission, enhanced neuronal plasticity 
and suppressed neuronal hyperexcitability in TgCRND8 mice AD model (Arrieta-Cruz et al., 2011). 
Beta blockers have been tested in AD clinical trials for the efficacy in reducing the disruptive 
behaviour, but not the cognitive improvement (Peskind et al. 2005). 
 
Lipid-lowering drugs 
 
High cholesterol levels have been positively correlated with a higher incidence of memory impairment 
and dementia. As reviewed elsewhere, epidemiology and preclinical statin research have generally 
supported an adverse role of high cholesterol levels regarding AD, while human studies of statins 
show highly variable outcomes, making it difficult to draw a firm conclusion (Hoyer and Riederer 2007; 
Shepardson et al. 2011a; 2011b). However, data from STZ-icv treated animal AD models, generally, 
demonstrate beneficial effects of lipid-lowering strategy (at least that with lipophilic characteristics) on 
STZ-icv induced cognitive deficits, which may be in line with the recent conclusion that differing blood-
brain barrier (BBB) permeability among statins, the stage in AD at which statins were administered 
and variation in the functional capacity of brain capillaries in AD and respective BBB transport, as well 
as the drugs' pleiotropic metabolic effects, may all contribute to the substantial variability observed in 
statin-AD research (Shepardson et al. 2011b). 
 
Pitavastatin and simvastatin (both lipophilic statins, dosed 10 mg/kg p.o. for 15 days) each 
significantly attenuated STZ-induced memory deficits and oxidative stress- and cholinergic deficit- 
related changes in mice (Dalla et al. 2010; Tramontina et al. 2011). However, fluvastatin (hydrophilic 
statin, dosed 10 mg/kg p.o. for 15 days) produced no significant effect on STZ-induced dementia or 
biochemical levels (Dalla et al. 2010). In a similar design, another lipid-lowering drug, ezetimibe (10 
mg/kg, orally for 15 days) also significantly attenuated STZ-icv induced memory deficits and oxidative 
stress changes in mice (Dalla et al. 2009). The effect of statins on tau aggregates and neurofibrillary 
tangles (NFT) has been investigated in a transgenic mouse tauopathy model where it was found that  
statins reduced NFT burden irrespective of blood-brain barrier permeability at both early and late ages 
in long- and short-term treatment paradigms and under normocholesterolemic and 
hypercholesterolemic conditions (Boimel et al. 2009). Results suggest that the anti- NFT effect of 
statins may be related to their anti-inflammatory and not necessarily to their cholesterol-lowering 
properties.  
 
Other therapeutic strategies 
 
Novel strategies in AD therapy, like inhibition of γ and β-secretases and passive immunization 
against β-amyloid, have been tested as amyloid-reduction therapy for Alzheimer's disease and are 
currently under investigation (as reviewed by Wollen 2010). Amyloid-reduction strategies have been 
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developed on the ground of the amyloid-cascade hypothesis that Aβ pathology is the primary 
neuropathological core, and therefore, interventions to reduce Aβ levels in the brain have become a 
promising approach in the sAD therapy research. One option is to change the activity of the enzymes 
involved in the amyloid precursor protein (APP) processing, but the major obstacle of γ-secretase 
inhibitors is their toxicity, while β-secretase inhibitors seems to be less toxic and effective in reducing 
the Aβ levels in the brain accompanied by improvement in cognitive decline in transgenic AD mice 
models (as reviewed by Ghosh et al. 2012). A small number of β-secretase inhibitors have entered 
early phase clinical trials. On the other hand, the immunisation therapy in clinical trials has been, in 
general, associated with a number of issues ranging from the neurological complications to the finding 
that anti-Aβ vaccination–induced Aβ clearance in the brain could still result in no cognitive benefit 
(Holmes et al. 2008). New approaches in immunisation are being tested now, the outcome of which, 
however, is uncertain yet but will be hopefully beneficial in future. In general, the problem with testing 
of the effectiveness of the β amyloid-reduction therapy in rodents is the developmental/structural lack 
of production of Aβ similar to the human one and consequently lack of its pathological aggregation in 
the form of senile plaques, which make it difficult to explore amyloid-reduction therapy in non-
transgenic rodents. This has been overcome by generating transgenic mice which overexpress the 
human Aβ-related genes. However, we have reported a time-dependent development of cerebral 
amyloid angiopathy in the STZ-icv treated rats (Salkovic-Petrisic et al. 2011), indicating that amyloid 
pathology should be more extensively explored and characterized in this model, which may then be 
hopefully exploited in the novel anti-AD drug testing. Until now, data is available from the experiments 
on transgenic mice AD models only (Dodart et al. 2002; Oddo et al. 2006; Tang and Ghosh 2011), 
while these novel strategies have not been explored in the STZ-icv animal models. 
 
Recent clinical data suggests that physical exercise, brain stimulation by cognitive training and 
socialization have beneficial effects on cognitive decline in AD patients, as reviewed elsewhere 
(Wollen 2010). Experimental data in STZ-icv treated animal AD models confirms these findings only 
partly. Physical exercise in the form of 14 day- or 5-week treadmill training, prevented cognitive 
deficits, oxidative stress and astrogliosis in the brain of STZ-icv treated rats (Jee et al. 2008; 
Rodrigues et al. 2010). The role of brain insulin in the exercise-induced cognitive improvement has 
been shown to be possibly induced through the regulation of mitochondrial H2O2 production, because 
a prior blockade of brain insulin signalling with STZ-icv injection abolished in mice the benefits of 
exercise on memory performance and mitochondrial H2O2 regulation (Muller et al. 2012). Therefore, 
four weeks of exercise did not prevent the STZ-icv induced cognitive deficits in this experiment on 
mice. Data on TgCRND8 mice AD model demonstrates that whether or not access to a running wheel 
has beneficial effects on Alzheimer-like pathology and symptoms may strongly depend on the exact 
time when the wheel is provided during development of the disease, which is important for the 
experimental design, and suggests also the importance of early introduction of physical exercise in the 
AD patients (Richter et al. 2008). 
 
CONCLUSIONS  
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It is difficult to establish an experimental animal model that would faithfully mimic the developmental 
pathology of the prevailing sporadic form of AD in humans. Widely exploited transgenic mice AD 
models, likeTG2576 and APP/PS1 mice models, resemble the familial form of AD, and, as suggested 
recently, actually simulate the asymptomatic phase of the disease and the results of interventional 
studies in these mice should be considered in the context of disease prevention, which is why these 
studies failed to predict results of human trials (Zahs and Ashe 2010).  
 
In line with the growing body of evidence suggesting that there may be different endophenotypes of 
sporadic AD (e.g. APOE4-negative
 
individuals, a pro-inflammatory phenotype or individuals with 
greater insulin resistance /Borroni et al. 2006/), representative animal models should mimic a specific 
endophenotype, such as STZ-icv treated animals which develop insulin resistant brain state. Data 
published until now, supports similar STZ-icv induced biochemical, structural and cognitive effects in 
all species investigated (rats, mice and monkeys), suggesting a kind of standardized and reproducible 
insulin-resistant brain state development and progression. STZ-icv animal sAD model demonstrates 
several advantages over the transgenic mice AD models: (i) gene manipulation is not inevitable 
starting point from the day of animal birth, (ii) pathological alterations in the brain can be initiated at 
any age of the previously intact animals, (iii) onset, development and progression of consequent 
cognitive deficits and associated biochemical and structural changes can be followed from the very 
moment of the brain damage induced by the STZ-icv injection, and (iv) this model provides the 
opportunity to assess the drug therapeutic potential in respect to the disease prevention, when given 
before or in parallel with STZ-icv injection, and the disease modification and progression, when given 
after the cognitive impairment has been manifested.  
 
Therapeutic strategies tested in the STZ-icv animal model until now have been involving most 
frequently drugs with predominant antioxidant activity. In general, the treatments were mostly initiated 
after the STZ-icv-induced brain damage, and therapeutic effectiveness was most frequently 
demonstrated at multiple levels, as a combination of improvement in cognitive and cholinergic deficit 
and oxidative stress condition. Effectiveness of most of the therapeutic strategies explored in STZ-icv 
model has been tested also in AD patients and comparable results has been found in many of the 
clinical trials. Nevertheless, some therapies failed to achieve comparable results on memory deficits in 
the STZ-icv animal models and clinical trials with sAD patients, like those with NSAIDs and PPAR γ 
agonists or vitamin E and Ginkgo biloba. Several reasons could account for that: (i) STZ-icv animal 
model has still not been fully characterized, (ii) parameters of memory assessment in animals and 
humans are different, the former based mostly on the deficits in spatial and fear-conditioned memory 
performance and the latter on scoring of conversation with patients by different questionnaires, (iii) 
drugs' pleiotropic effects in addition to their antioxidant, anti-AChE and anti-inflammatory properties as 
well as different patient comorbidity can contribute to the substantial variability of the drug efficacy 
between the STZ-icv animal models and sAD patients, and (iv) different dosing regime in the human 
and animal studies (post STZ-icv observational period ≤3 months; drug treatment ≤1 month), sAD 
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endophenotype and stage of disease at which the drugs were administered in comparison with the 
corresponding disease stage in STZ-icv treated animals.  
 
The last mentioned one might be of a particular importance in a view of our recent experiments of a 9-
month follow up of the STZ-icv rats (manuscript in preparation) which have demonstrated that 
cognitive and neurochemical changes follow the similar time-dependent pattern (≤1 month - acute 
response; 1-3 months- tendency to return to normal values; 6-9 months - decompensation phase with 
a slow and progressive aggravation). Such pattern seems to resemble the situation in a real life where 
sAD might be triggered by some gene-environmental interactions (Salkovic-Petrisic et al. 2010), and 
yet, it does not exists in the transgenic mice AD models. Therefore, careful designing of drug 
interventional studies in the STZ-icv animal sAD model, in line with the STZ-icv dose- and time-
dependent pattern of pathophysiology, might provide better predictive value in translating the results to 
humans. STZ-icv non-transgenic sAD model represents a promising experimental tool by providing 
new insights concerning both early and late brain alterations which can be translated in novel 
etiopathogenic and therapeutic approaches in this disease.  
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Figure 1. Therapeutic strategies tested in streptozotocin-intracerebroventricularly-treated (STZ-icv) animal 
model of sporadic Alzheimer’s disease (sAD). Interventional drug treatments in the STZ-icv animal model of sAD 
have been presented in regard to the effectiveness in the STZ-icv model in relation to the investigated 
parameters of cognition and/or brain neurochemistry and initiation of the drug treatment in relation to the 
STZ-icv administration (pre- or post-treatment). Furthermore, results are expressed in relation to the type of 
the treatment strategy/mechanism of drug action tested in STZ-icv animal model and treatment-induced 
improvement in various parameters. Finally, comparison to the effectiveness of the same therapeutic 
strategies in clinical trials has been presented. Except for the last one where effectiveness in clinical trials is 
expressed by number of therapeutic approaches performed in STZ-icv model (one approach may cover more 
than one exact experiment), all other results are expressed as number of exact experiments performed in STZ-
icv model until April 2012. Experiments with Indian and Chinese herbal drugs have been excluded. 
